🔎 Trials Near Me

Hem › Burkitts lymfom › Illinois

Kliniska studier för Burkitts lymfom i Illinois

14 studier för Burkitts lymfom söker deltagare vid platser i Illinois.

Städer i Illinois

Officiell studietext (engelska)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • och 4 fler
RekryterarFas 2
366 Days – 46 Years · Alla kön · Uppdaterad 2 okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
  • och 7 fler
RekryterarFas 3
Ålder 18 till 39 · Alla kön · Uppdaterad 2 okt. 2026 · NCT03150693

Blinatumomab Consolidation in Real World

  • Northwestern University, Chicago
  • The University of Chicago, Chicago
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • och 9 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • Advocate Children's Hospital-Oak Lawn, Oak Lawn
  • och 3 fler
RekryterarFas 2
365 Days · Alla kön · Uppdaterad 25 sep. 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • och 2 fler
RekryterarFas 2
Ålder 1 till 30 · Alla kön · Uppdaterad 1 sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • och 5 fler
RekryterarFas 3
365 Days – 25 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekryterarFas 2
Ålder 7 till 25 · Alla kön · Uppdaterad 19 aug. 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, Chicago
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 19 aug. 2026 · NCT06137118

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  • Research Site, Chicago
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 13 juli 2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • University of Chicago Comprehensive Cancer Center, Chicago
RekryterarFas 2
Ålder 18 till 54 · Alla kön · Uppdaterad 17 mars 2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

  • University of Chicago Comprehensive Cancer Center, Chicago
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 4 nov. 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  • University of Chicago, Chicago
RekryterarFas 1/2
Ålder 15 till 50 · Alla kön · Uppdaterad 9 sep. 2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Rekryterar
Ålder 18 till 50 · Alla kön · Uppdaterad 19 juni 2025 · NCT06785324

Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.